U.S. Benign Prostatic Hyperplasia Markets

Published by: Frost & Sullivan

Published: Oct. 24, 2005

Table of Contents

1. Executive Summary

   1. Executive Summary

      1. Executive Summary

2. Introduction to Benign Prostatic Hyperplasia

   1. Introduction to Benign Prostatic Hyperplasia

      1. Benign Prostatic Hyperplasia Overview

      2. Scope and Segmentation

   2. Basic Benign Prostatic Hyperplasia Terminologies and

      Definitions

      1. Basic Benign Prostatic Hyperplasia Terminology

      2. The History of Benign Prostatic Hyperplasia

      3. Benign Prostatic Hyperplasia Diagnosis

      4. Benign Prostatic Hyperplasia Complications

3. U.S. Benign Prostatic Hyperplasia Market Segments

   1. Disease and Treatment Overview

      1. Benign Prostatic Hyperplasia Prevalence

      2. Treated Population Forecast

      3. Urologist and Primary Care Physician Practice Patterns

   2. Product Analysis

      1. Overview

      2. Minimally Invasive Therapy

      3. Watchful Waiting and Medical Therapy

      4. Alpha Adrenergic Antagonists Therapy

      5. Alpha Reductase Inhibitor Therapy

      6. Combination Therapy

4. U.S. Benign Prostatic Hyperplasia Markets

   1. Competitive and Product Analysis

      1. Competitive Landscape

      2. Landmark Studies

      3. SWOT Analysis of Current Medications

      4. Competitor Profiles

      5. Pipeline Analysis

      6. Anticipated Launch Dates

   2. Market Forecasts

      1. Revenue Forecasts

      2. Pricing Trends

      3. Key Patent Expiration

   3. Frost & Sullivan Awards

      1. Marketing Strategy Leadership of the Year Award

      2. Industry Innovation Advancement of the Year Award

      3. Technology Innovation of the Year Award

      4. Product Differentiation Innovation of the Year Award

5. Appendix

   1. Decision Support Databases

      1. Physicians

      2. Urologists

      3. Prostate Cancer Incidence

      4. Prostate Cancer Mortality

      5. Total Population

List Of Figures

Chapter 2

• Benign Prostatic Hyperplasia Market: American Urological Association Symptom Severity Index (U.S.), 2004

Chapter 3

• Benign Prostatic Hyperplasia Market: Symptomatic Prevalence Forecasts (U.S.), 2001-2011


• Benign Prostatic Hyperplasia Market: Symptomatic Medically Treated Patient Forecasts (U.S.), 2001-2011


• Benign Prostatic Hyperplasia Market: How Treatment Strategies Have Changed Over the Past Five Years (U.S.), 2004


• Benign Prostatic Hyperplasia Market: Anticipated Changes in BPH Therapy Over the Next Five Years (U.S.), 2004


• Benign Prostatic Hyperplasia Market: Comparison of Select Minimally Invasive Therapies and Surgery (U.S.), 2004


• Benign Prostatic Hyperplasia Market: Current Medications on the Market (U.S.), 2004


• Benign Prostatic Hyperplasia Market: Benchmarking Efficacy for BPH Medication (U.S.), 2004

Chapter 4

• Benign Prostatic Hyperplasia Market: SWOT Analysis of Current Medications (U.S.), 2004


• Benign Prostatic Hyperplasia Market: Competitor Profiles (U.S.), 2004


• Benign Prostatic Hyperplasia Market: Therapeutics in Development (U.S.), 2005


• Benign Prostatic Hyperplasia Market: Total Revenue Forecasts (U.S.), 2001-2011


• Benign Prostatic Hyperplasia Market: Annual Cost of Therapy of Popular Medications (U.S.), 2003-2004

Abstract

Shifting Focus from Symptom Relief to Disease Management to treat Benign Prostatic Hyperplasia Increases the Treated Population Base

There is tremendous potential for the U.S. benign prostatic hyperplasia (BPH) market, considering only 20 percent of the affected population was treated in 2004. New treatment regimens are expected to tap the prospects more thoroughly and improve the market reach of BPH companies. The market can take heart from landmark studies such as Prostate Cancer Prevention Trials, which proved that medical treatment is vital to slow down disease progression in high-risk patients and reduce the prevalence of prostrate cancer. These findings could cause a shift in treatment practice from symptom relief to long-term disease management. Physicians are expected to do away with the cautious ‘watchful waiting’ approach for patients with mild symptoms and instead, prescribe medication for patients at high risk of disease progression. Advanced studies will help detect new parameters involved in BPH disease progression, which can help identify patients for early treatment. This will broaden the BPH treated patient base substantially.

This Frost & Sullivan research service provides data and analysis on the U.S. BPH markets. It analyzes related indications such as lower urinary tract symptoms (LUTS) and complications such as acute urinary retention (AUR). The study also discusses the competitive factors within the BPH markets including patient and revenue forecasts, product differentiation, clinical trials, and pipeline therapies. The research service enables companies to align their positioning strategies to benefit from the changing market conditions and obtain maximum return on investment.

Expansion of Indications for Treating Comorbid Conditions to Drive the BPH Market

Comorbidities are common among men aged 50 and above due to their numerous health and lifestyle challenges. "Erectile dysfunction, overactive bladder (OAB), coronary artery disease, and male pattern baldness are all comorbidities that are highly prevalent among BPH patients," says the analyst of this research service. "Having one medication that can address various conditions will provide a strong competitive advantage for a branded product and such drugs will also offer some protection from generic erosion."

With the proven correlation of high-grade androgenic male pattern baldness and BPH, Propecia, an approved drug for BPH and male pattern baldness comorbidity, is expected to be hugely successful. Similarly, Detrol LA (tolterodine), which is approved for OAB and in clinical trials for BPH, is likely to be a clear favorite among the many BPH patients with LUTS. Cialis (tadanafil), which has been approved for the treatment of erectile dysfunction and in clinical trials for BPH, is expected to be another very popular drug.

Participants Seek Additional Revenue Streams from New and Untapped Markets

Escalating competition and product maturity are compelling BPH drug suppliers to look for new growth opportunities in novel segments such as LUTS and AUR. This drive to introduce new medication can expand the market considerably to include the female population afflicted with LUTS. LUTS may be caused due to various reasons and can occur along with conditions such as BPH, OAB, or others.

"Similarly, Sanofi-Aventis is seeking an AUR indication for its product Uroxatral," notes the analyst. "This is expected to expand Uroxatrals clinical utility beyond BPH-related causes of AUR."

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.